



(12) **United States Patent**
Carlsgaard et al.

(10) **Patent No.:** **US 9,990,581 B2**
(45) **Date of Patent:** **Jun. 5, 2018**

(54) **INSULIN DOSAGE ASSESSMENT AND RECOMMENDATION SYSTEM**

2010/0198520 A1 8/2010 Breton et al.
2011/0021898 A1 1/2011 Wei et al.
2011/0208027 A1 8/2011 Wagner et al.

(75) Inventors: **Peter B. Carlsgaard**, Zionsville, IN (US); **Christen Rees**, Indianapolis, IN (US); **Robin S. Wagner**, Indianapolis, IN (US)

(73) Assignee: **Roche Diabetes Care, Inc.**, Indianapolis, IN (US)

(*) Notice: Subject to any disclaimer, the term of this patent is extended or adjusted under 35 U.S.C. 154(b) by 798 days.

(21) Appl. No.: **13/546,447**

(22) Filed: **Jul. 11, 2012**

(65) **Prior Publication Data**

US 2014/0019396 A1 Jan. 16, 2014

(51) **Int. Cl.**
G06N 5/02 (2006.01)
G06F 19/00 (2018.01)
A61M 5/172 (2006.01)

(52) **U.S. Cl.**
CPC **G06N 5/02** (2013.01); **A61M 5/1723** (2013.01); **G06F 19/345** (2013.01); **G06F 19/3468** (2013.01)

(58) **Field of Classification Search**
None
See application file for complete search history.

(56) **References Cited**

U.S. PATENT DOCUMENTS

7,404,796 B2 7/2008 Ginsberg
2003/0216628 A1 11/2003 Bortz et al.

OTHER PUBLICATIONS

Thorne, "Attitudes toward patient expertise in chronic illness," Intl J Nursing Studies, 37, 303-311, 2000.*
Hornsten, "Nurses' experiences of conflicting encounters in diabetes care," EDN Summer, 5(2), 64-69, 2008.*
DAFNE Study Group, "Training in flexible, intensive insulin management to enable dietary freedom in people with type 1 diabetes: dose adjustment for normal eating (DAFNE) randomised controlled trial," vol. 325, 6 pages, 2002.*

(Continued)

Primary Examiner — G. Steven Vanni

(74) Attorney, Agent, or Firm — Harness Dickey

(57) ABSTRACT

A computer-implemented method is presented for recommending insulin dosage adjustments for a patient having diabetes. The method includes: identifying a plurality of bolus events from patient data; grouping bolus events having a recommended bolus dosage substantially equivalent to the amount of administered insulin into a first subset of bolus events; determining a bolus outcome for each of the bolus events in the first subset of bolus events, where the bolus outcome is expressed in relation to a target range of blood glucose values and is selected from a group including above the target range, in the target range and below the target range; determining whether one of the bolus outcomes is predominant amongst the bolus events in the first subset of bolus events; and generating a recommendation pertaining to insulin dosage for the patient in response to a determination that one of the bolus outcomes is predominant.

13 Claims, 8 Drawing Sheets

